secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001564590-21-043726
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology Q2 2021 net loss $12.7M; cash $264M, IK-412 IND delayed by supply
--------------------------------------------------------------------------------

- Cash and cash equivalents $264.0M as of June 30, 2021; expected to fund operations through 2023.
- Net loss $12.7M in Q2 2021 vs $5.0M in Q2 2020; R&D expense $11.4M vs $6.3M.
- IK-930 IND submission on track for end of 2021; preclinical data at EORTC-NCI-AACR conference.
- IK-175 monotherapy expansion cohort enrolling additional bladder cancer patients; clinical data planned in 2022.
- IK-412 IND submission delayed due to shortage of a component required for COVID-19 vaccines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/0001564590-21-043726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000156459021043726/ikna-8k_20210812.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer